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Abstract
Between January and June 2017, Malta held the Presidency of the 
Council of the European Union (EU). One of its thematic priorities 
was Structured Cooperation between health systems. Evidence for 
strengthened cooperation in the areas of procurement of health 
technologies and delivery of highly specialised services was presented 
and discussed in a series of meetings. Council Conclusions were 
elaborated and an ambitious cooperation declaration between Southern 
European countries in the area of access to innovative medicines was 
signed. This article describes the rationale for these linked activities 
as a means to support European health systems in addressing critical 
challenges that cannot be tackled by Member States acting alone. These 
cooperation initiatives are important in the light of the evolving debate 
on the Future of Europe and the role that health policy should play in 
the European Union post 2020. Malta, as a small Member State with an 
open market, is often exposed earlier and more harshly to the impacts 
of market and environmental changes on its health system. It can 
therefore play an important role in scanning the horizon for potential 
impacts and proposing appropriate policy responses at European level.
The European added value 
of health system cooperation 
to ensure access to innovative 
medicines and technologies
Educational aims
•	 To increase awareness about the role played by the Maltese Presidency of the 
Council of the European Union
•	 To appreciate the potential of increased cooperation between health systems as a 
mechanism to address critical health system challenges
•	 To gain an understanding of the state of play in regional country cooperation to 
improve access to innovative medicines and technologies
The contribution made by the Maltese Presidency of the Council of the European Union  
January-June 2017 to strengthen health system cooperation
Introduction
In January 2017, for the first time in history, 
Malta took up the Presidency of the Council 
of the EU. As is customary, Malta presented 
its thematic priorities for discussion and 
debate. In the health sector, one of the 
two main priorities presented was that of 
‘Structured Cooperation between Health 
Systems’.1 This was defined as “Voluntary 
and organized cross-border activity between 
health care sector actors (e.g. governments, 
health agencies, providers, professional 
bodies, funders, educational institutions and 
others)”.2 Article 168(7) of the Treaty of 
the EU makes it clear that when it comes 
to health systems, Member States are in 
the driving seat and Union action shall 
complement the efforts of Member States.3 
Traditionally, there have been serious 
tensions between Member States and the EU 
on issues related to health systems at EU 
level.4 The Maltese Presidency by proposing a 
voluntary approach, took into consideration 
the existing tensions whilst attempting 
to propose a solution that would allow 
those Member States who wish to do more 
together to do so in an effective manner 
with continuity, structure and support from 
the European institutions. This multi speed 
Europe approach is one of the options put 
forward for consideration on the Future 
of Europe White Paper by the Juncker’s 
European Commission as Europe deliberates 
on its future post 2020 and post Brexit.5 
Rationale
The Maltese Presidency chose to focus upon 
improving health systems cooperation with 
a view to finding ways to enhance access 
to innovative medicines, technologies and 
highly specialised services for European 
citizens. In its approach, the Presidency 
sought to emphasise the word voluntary 
when talking about structured cooperation 
since following the experience of the 
patients’ rights and cross-border directive, 
the need to promote the idea of moving 
away from a one size fits all approach in the 
health sector was acknowledged. Increasing 
cross-border health system cooperation was 
proposed as one of the solutions that can 
be used to address commonly experienced 
challenges arising due to circumstances 
beyond the control of national policy more 
effectively. The rationale considered that 
cooperation with other health systems 
may lead to enhanced efficiency thereby 
contributing towards the health system 
sustainability objective.
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States agreed to establish a technical 
committee to explore voluntary cooperation 
in areas including; sharing information, 
identifying best practices, horizon scanning, 
price negotiations and joint procurement. 
The values of trust, loyalty, solidarity and 
transparency were underlined as being key 
to the success of this initiative.
Discussion
Health systems are currently facing a ‘perfect 
storm’ with multiple challenges producing 
a strong force that is challenging the 
status quo and traditional way of funding 
and organising health services. Changes in 
information technology (IT), changes in 
citizen and patient expectations, the new 
medicines and technology pipeline, genetic 
therapies, changes in payment systems 
and changes in provider configurations 
are some of the key issues that are 
coinciding to produce a serious effect 
on access and sustainability of European 
health systems. Furthermore, the nature of 
developments in medicine and the evolution 
of the pharmaceutical market means that 
mechanisms that may have worked in the 
past to secure access at sustainable prices 
will no longer continue to produce the 
desired results. As a consequence, it appears 
that there is a clear added value for health 
systems to work more closely together. The 
following areas emerge specifically as focus 
areas in which cross border cooperation can 
be strengthened: collation of data, evidence 
and knowledge in the post-marketing/
procurement phase, new ways of funding – 
new financial instruments (bonds system, 
data for discounts, grouping of countries to 
enable negotiations for larger populations 
and increase bargaining power).7 These 
considerations are particularly relevant for 
the areas of rare diseases and personalised 
health care.
Member States have shown interest in 
coming together in groups to try and address 
the issue of access to innovative medicines 
more cost-effectively. A number of agreements 
have been signed in past months incuding 
the BENELUXA, Baltic, Visegrad and during 
the Maltese Presidency the Valletta group of 
Southern European countries, including Cyprus, 
Greece, Italy, Malta, Portugal, Spain joined by 
Ireland and Romania. The expectation is that 
by pooling capacities and bargaining power, 
Member States would be better able to address 
the market asymmetry between industry and 
governments, particularly for smaller Member 
States. This of course will depend upon the 
willingness of the pharma industry to engage 
in meaningful dialogue. In this sense, the 
adoption of terms of reference for a more 
permanent forum between Member States and 
industry achieved through the efforts of the 
Maltese Presidency is an important step in this 
process. 
The adoption of Council Conclusions on 
Encouraging Member States driven Voluntary 
Cooperation between Health Systems provides 
a framework within which several actions 
can be developed in the coming years.9 The 
following are amongst the key priorities 
identified:
•	 Better anticipation of the impact of new 
medicines and technologies on health 
systems through more coordinated 
horizon scanning
•	 An emphasis on the monitoring during 
the post-marketing phase, to evaluate 
the outcomes, including the impact, 
that adoption of innovative health 
technologies has on patient and on 
health systems
•	 Exchange information to increase 
transparency and improve the leverage of 
individual Member States’ in negotiations 
with industry
As discussions on the role of the future of 
Europe unfold, it is important to ensure that 
the public health objectives and health system 
dimension remain firmly embedded in the 
The Maltese health system is well placed 
to steer this discussion at a European level 
for the following reasons. Cross border 
cooperation is an intrinsic characteristic 
of the Maltese health system with long-
standing practical experience in both 
structured patient mobility (e.g. patients 
travelling overseas for treatment of rare 
diseases) and structured professional 
mobility (for specialist training purposes).6 
Secondly the Maltese health system with its 
small market characteristics has been faced 
with challenges in securing affordable access 
to innovative medicines for cancer and rare 
diseases, but this issue is now mainstream 
on the European (global) policy agenda 
and therefore a window of opportunity for 
concrete action is available.
Process
In order to construct an informed debate, 
the Maltese Presidency commissioned the 
production of two policy briefs by the 
European Observatory on Health Systems and 
Policies to answer the following questions:
•	 How can structured cooperation 
between countries address health 
workforce challenges related to 
highly specialized health care?2
•	 How can voluntary cross-border 
collaboration in public procurement 
improve access to health technologies 
in Europe?7
The Presidency, through the Ministry 
for Health, organised a series of meetings 
where the above topics were discussed. 
These included a workshop on Structured 
Cooperation between Health Systems, 
an informal meeting for Directors of 
Pharmaceutical Policy, the meeting of 
Competent Authorities for Pricing and 
Reimbursement of Medicines and the 
Pharma Round Table of Health Minister 
with Industry. These items were also on the 
agenda of the Informal Health Ministers 
meeting as well as the EPSCO Council where 
Council Conclusions were presented for 
adoption. Under the Maltese Presidency, 
eight EU Member States (Cyprus, Greece, 
Ireland, Italy, Malta, Romania, Portugal, 
Spain) signed up to the Valletta declaration.8 
In this declaration, these Member States 
agreed to cooperate to be in a position 
to better guarantee patient access to 
innovative medicines and therapies whilst 
ensuring health system sustainability. In 
order to achieve this objective, the Member 
Key points
•	 Between January and June 2017 Malta took up the Presidency of the Council of the EU
•	 Improving health systems voluntary cooperation to enhance access to innovative 
medicines, technologies and highly specialised services for European citizen was a key 
priority
•	 Eight countries signed the Valletta declaration to cooperate to better guarantee 
patient access to innovative medicines and therapies whilst ensuring health system 
sustainability
•	 The adoption of Council Conclusions on Encouraging Member States driven Voluntary 
Cooperation between Health Systems provides a strong legacy for the Maltese Presidency
Issue 23  20176          Journal of the Malta College of Pharmacy Practice
context of promoting pharmaceutical policy 
and industry within the European Union. 
In this way, it will be possible to strike the 
much-needed balance between promoting 
the European Union as a hub for innovation 
and industrial growth alongside assurance 
of equitable access to this innovation by 
all European Union citizens irrespective of 
where they reside. 
Conclusion
Developments in the medicines pipeline 
and changes to the medicines regulatory 
framework are placing increased pressure on 
health systems to rethink their approach to 
ensure sustainable access to innovation. This 
issue is being dealt with at an international 
level through several fora. The Maltese 
Presidency, through its policy proposals 
and discussions has made an important 
contribution in taking this agenda forward 
within the European Union10 and has left a 
strong legacy upon which further work can 
be carried out.11 
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